Abstract: Provided herein are compounds of Formula (I), Formula (II), and Formula (III), and compositions comprising the same, as well as methods of use thereof for controlling or inhibiting the formation of calcium oxalate kidney stones, inhibiting the production of glyoxylate and/or oxalate, and/or inhibiting hydroxyproline dehydrogenase (HYPDH).

Abstract: Provided herein is a delivery system, including: (a) an optical sensor configured to detect data to create a map of a patient bodily surface; and (b) a dispenser operatively associated with the optical sensor and configured to deliver compositions (optionally including cells) to the patient bodily surface based upon the data or map. Methods of forming a tissue on a patient bodily surface of a patient in need thereof are also provided, as are methods, systems and computer program products useful for processing patient bodily surface data.

Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.

Abstract: Modified alginates are described herein along with hydrogels comprising the same. A modified alginate may be prepared by reacting alginate and an aromatic compound (e.g., an aromatic amine) and/or pH sensitive compound. The modified alginates, hydrogels, and/or methods described herein may be used to coat and/or encapsulate at least a portion of a bioactive substance, optionally for oral delivery in humans and other animals.

Abstract: Provided herein is a delivery system, including: (a) an optical sensor configured to detect data useful to create a map of a bodily surface; and (b) a printer operatively associated with the optical sensor and configured to deliver compositions (optionally including cells) to the bodily surface based upon the data or map. Methods of forming a tissue on a bodily surface of a patient in need thereof are also provided, as are methods, systems and computer program products useful for processing bodily surface data.

Abstract: A method of treating hypoxic tissue such as wound tissue comprises contacting a composition to the hypoxic tissue in a hypoxia-treatment effective amount, the composition comprising a biodegradable polymer and an inorganic peroxide incorporated into the polymer.

Abstract: A method of treating hypoxic tissue such as wound tissue comprises contacting a composition to the hypoxic tissue in a hypoxia-treatment effective amount, the composition comprising a biodegradable polymer and an inorganic peroxide incorporated into the polymer.

Abstract: The invention relates generally to systems and methods of bioenergetic profiling, uses thereof, and systems and devices relating thereto. In particular, methods of the invention are useful in assessing wellness, particularly in elderly subjects. Described are systems and methods of assessing likelihood of subject morbidity, life expectancy, positive clinical outcome, responsiveness to treatment, and certain disease states as well as of selecting treatment strategy, improving outcome to treatment strategy, and treating subjects with low bioenergetic profiles. Also described are devices and systems for measuring respiratory capacity.

Abstract: Compositions and methods useful for diagnosis and prognosis of cancer are provided. More particularly, methods for detecting breast or prostate cancer protein or nucleic acid biomarkers consisting of iron homeostasis biomarkers in a biological sample obtained from a subject are provided.

Abstract: Disclosed herein are systems and methods for specifying treatment criteria and treatment planning parameters for patient specific radiation therapy planning. According to an aspect, a method includes receiving data about a patient, computing geometric characterization of one or more organs at risk proximate to a target volume of a patient or vice versa, and selecting relevant treatment knowledge and experience. The method also includes generating, based on the received data, computed geometric characterization, and available knowledge and experience, a first set of radiation treatment planning parameters that will lead to a high quality plan for the patient. Further, the method includes model-based prediction, based on the data, a second set or more of radiation treatment planning parameters that will lead to alternative achievable plans with different organ sparing objectives for treating the patient. The multiple sets for parameters can be used separately or in conjunction to generate treatment plans.

Abstract: The present invention provides methods of assessing an individual subject's risk of developing prostate cancer, comprising: a) analyzing a nucleic acid sample obtained from the subject and determining a genotype for the subject at a plurality of biallelic polymorphic loci, wherein each of said plurality has an associated allele and an unassociated allele, wherein the genotype is selected from the group consisting of homozygous for the associated allele, heterozygous, and homozygous for the unassociated allele; and b) calculating a cumulative relative risk (CRR) for the subject based on the genotype determined in step (a). A CRR of greater than 1.00 identifies a subject as having an increased risk of developing prostate cancer and also can identify a subject who is a candidate for early PSA screening, prostate biopsy and/or chemoprevention.

Abstract: Provided herein are keratin compositions (e.g., keratin gels, scaffolds, particulates, and the like) including a compound of interest, useful for release and/or delivery of the compound of interest (e.g., in vivo or in vitro). In some embodiments, the composition is a composition formulated for controlled release of the compound of interest.

Abstract: A method of treating a sphincter deficiency disorder (e.g., incontinence; gastrointestinal disorders) is carried out by administering stromal cell-derived factor 1 (SDF-1) to a sphincter or sphincter complex, such as a urethral or gastrointestinal sphincter (e.g., a rectal sphincter) of the subject in a treatment-effective amount.

Abstract: Provided herein are urine progenitor cells and methods for producing a culture of urine progenitor cells from a urine sample. The cells may be selected based upon the use of a selective cell medium, based upon morphology, and/or by selecting cell-specific markers. Also provided is an isolated urine progenitor cell that is c-kit positive and can differentiate into urothelium, smooth muscle, endothelium or interstitial cells. Methods of use of urine progenitor cells are provided, wherein cell are seeded onto a tissue scaffold are provided. Methods of treating a subject in need thereof are also provided, including providing a bladder tissue substrate that includes differentiated UPCs and transplanting the substrate into the patient. Finally, kits are provided that include a container suitable for the transport of a urine sample; media; one or more antibiotics; a package for holding said container, media, and antibiotics; and optionally, instructions for use.

Abstract: A composition comprising microcapsules, the microcapsules containing both live mammalian ovarian granulosa cells and live mammalian ovarian theca cells, is described. In some embodiments, the granulosa cells and the theca cells are contained in separate microcapsules in the composition; in some embodiments, the granulosa cells and the theca cells are contained together in the same microcapsules in the composition. The composition is can be used for estrogen, and optionally also progesterone, delivery, and hence is preferably free or essentially free of oocytes. Methods of using the same and pharmaceutical formulations containing the same are also described.

Abstract: Differentiation and stability of neural stem cells can be enhanced by in vitro or in vivo culturing with one or more extracellular matrix (ECM) compositions, such as collagen I, IV, laminin and/or a heparan sulfate proteoglycan. In one aspect of the invention, adult mammalian enteric neuronal progenitor cells can be induced to differentiate on various substrates derived from components or combinations of neural ECM compositions. Collagen I and IV supported neuronal differentiation and extensive glial differentiation individually and in combination. Addition of laminin or heparan sulfate to collagen substrates unexpectedly improved neuronal differentiation, increasing neuron number, branching of neuronal processes, and initiation of neuronal network formation. In another aspect, neuronal subtype differentiation was affected by varying ECM compositions in hydrogels overlaid on intestinal smooth muscle sheets.

Abstract: Angiotensin (1-7) analogs are provided. Also provided are methods of making such analogs methods for using analogs as therapeutic compositions such as, for example, treatment cancer.

Abstract: A process for assessing risk that administration of a substance will suppress immune competence in a population of subjects is provided. Such a substance may be a substance related to, contained in or derived from a tobacco product or, more generally, a substance concerning which it is desired to assess risk of administration of the substance.

Abstract: The invention provides compositions and methods for identifying autism and autism spectrum disorders in humans. The invention also includes compositions and methods for identifying unique gene expression profiles in children with regressive autism spectrum disorder (ASD) and ileocolitis.